BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38583049)

  • 1. [Clinical features of patients with metastatic pheochromocytoma/paraganglioma].
    Cui YY; Zhou Y; Gao YJ; Li TY; Wang Y; Zhang WQ; Zhou T; Chen S; Tong AL
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1174-1179. PubMed ID: 38583049
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.
    Buffet A; Ben Aim L; Leboulleux S; Drui D; Vezzosi D; Libé R; Ajzenberg C; Bernardeschi D; Cariou B; Chabolle F; Chabre O; Darrouzet V; Delemer B; Desailloud R; Goichot B; Esvant A; Offredo L; Herman P; Laboureau S; Lefebvre H; Pierre P; Raingeard I; Reznik Y; Sadoul JL; Hadoux J; Tabarin A; Tauveron I; Zenaty D; Favier J; Bertherat J; Baudin E; Amar L; Gimenez-Roqueplo AP;
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1109-1118. PubMed ID: 30698717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
    Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
    Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recurrence and metastasis of pheochromocytoma/paraganglioma after tumor resection and clinical characteristics analysis].
    Gao YJ; Cui YY; Ma XS; Wang HP; Liu J; Lou FC; Zhou T; Chen S; Lu L; Tong AL
    Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):729-734. PubMed ID: 35280017
    [No Abstract]   [Full Text] [Related]  

  • 6. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
    Wang LL; Wei XJ; Zhang QC; Li F
    Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
    Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
    Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study.
    Ma X; Li M; Tong A; Wang F; Cui Y; Zhang X; Zhang Y; Chen S; Li Y
    Front Endocrinol (Lausanne); 2020; 11():574662. PubMed ID: 33362715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
    King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
    J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
    Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
    Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
    Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
    Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
    Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
    Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
    Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel SDHB c.563 T > C mutation responsible for Paraganglioma syndrome and genetic analysis of the SDHB gene in China: a case report.
    Chen H; Yao W; He Q; Yu X; Bian B
    BMC Med Genet; 2020 May; 21(1):116. PubMed ID: 32460727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
    Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
    Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One genotype, many phenotypes: SDHB p.R90X mutation-associated paragangliomas.
    Alzahrani AS; Alswailem M; Moria Y; Aldeheshi A; Al-Hindi H
    Endocrine; 2020 Dec; 70(3):644-650. PubMed ID: 32804377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International initiative for a curated
    Ben Aim L; Maher ER; Cascon A; Barlier A; Giraud S; Ercolino T; Pigny P; Clifton-Bligh RJ; Mirebeau-Prunier D; Mohamed A; Favier J; Gimenez-Roqueplo AP; Schiavi F; Toledo RA; Dahia PL; Robledo M; Bayley JP; Burnichon N
    J Med Genet; 2022 Aug; 59(8):785-792. PubMed ID: 34452955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.